Bioventus (BVS) Net Income towards Common Stockholders (2020 - 2026)

Bioventus (BVS) has 6 years of Net Income towards Common Stockholders data on file, last reported at $3.9 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 218.78% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.5 million (up 1139.8% YoY) and the FY2023 annual result came in at -$74.4 million, down 8.28% from the prior year.
• Net Income towards Common Stockholders declined to $3.9 million in Q1 2026, from $17.3 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $17.3 million in Q4 2025 to a low of -$74.4 million in Q2 2023.
• A 4-year average of -$11.2 million and a median of -$340500.0 in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 93484.0% — and 2026, when it jumped 218.78%.
• Tracing BVS's Net Income towards Common Stockholders over 4 years: stood at -$23.4 million in 2022, then plunged by 218.13% to -$74.4 million in 2023, then soared by 123.27% to $17.3 million in 2025, then sank by 77.21% to $3.9 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $3.9 million (Q1 2026), $17.3 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.